Glaukos Corporation
HealthcareNYSE:GKOS · New York Stock Exchange
+$2.55 today
Vol 0.56M · Avg 0.94M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.6%
avg -14.8%
ROIC
-10.6%
avg 7.0%
ROA
-21.0%
avg -9.9%
Analysis
ROIC is currently the strongest return metric at -10.6% versus its period average of 7.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph E. Gilliam | President & Chief Operating Officer | $1.29M | — | 50 | $73,419.00 | 0.13% |
Tomas Navratil | Chief Development Officer | $1.02M | — | 49 | $90,402.00 | 0.15% |
Thomas William Burns | Chairman & Chief Executive Officer | $856,643.00 | — | 65 | $73,026.00 | 0.12% |
Alex R. Thurman | Senior Vice President & Chief Financial Officer | $501,950.00 | — | 56 | $53,681.00 | 0.09% |
L. Jay Katz FACS | Chief Medical Officer | — | — | — | — | — |
Christopher William Lewis | Vice President of Investor Relations & Corporate Affairs | — | — | — | $73,026.00 | 0.12% |
Michele Allegretto | Senior Vice President of Human Resources | — | — | — | — | — |
Jane E. Rady | Senior Vice President of Corporate Strategy & Business Development | — | — | 78 | — | — |
Robert L. Davis | Senior Vice President, General Counsel & Business Development | — | — | 60 | — | — |
Diana A. Scherer | Vice President of Compliance & Deputy General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
38
$36.55M
Net Sentiment
$36.55M
Net selling
Most Active
Navratil Tomas
12 transactions
1–10 of 38
Analysis
Insiders reported 0 buys worth $0.00 and 38 sells worth $36.55M over the last 12 months. That adds up to net selling of $36.55M. Navratil Tomas was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +29.8% (14yr)6 analysts |
| Revenue | N/A | N/A | +76.1% | +20.5% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | +33.7% (14yr)6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +76.1% over three years. Forward estimates point to Net Income at +33.7% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Bruker Corporation
NASDAQ:BRKR
$8.26B
Alkermes plc
NASDAQ:ALKS
$7.38B
Oscar Health, Inc.
NYSE:OSCR
$7.33B
Arcellx, Inc.
ACLX
$6.73B
Teleflex Incorporated
NYSE:TFX
$5.78B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
iRhythm Technologies, Inc.
NASDAQ:IRTC
$3.73B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.52B
Who manages GKOS?
Glaukos Corporation (GKOS) lists 10 active executives. The top listed executive is Tomas Navratil, Chief Development Officer.
Are GKOS insiders buying or selling?
Recent insider activity shows net selling of $22.19M.
Explore More
Continue the stock analysis
Jump to another research area for this company.